|
Paris, february 03, 2010 - EMEA gives official scientific advice on clinical Phase IIb efficacy study of inecalcitol in hormone-refractory prostate cancer. |
|
|
Paris, January 06, 2010 - the French drug agency, AFSSAPS (“Agence Française de Sécurité Sanitaire des Produits de Santé”), approved an amendment to the current clinical tolerance Phase IIa study in hormone-refractory prostate cancer patients. The amendment allows the 4 milligram oral dose of inecalcitol to be tested once- and twice-a-day. |
|
|
Paris, November 13, 20009 - Pre-submission meeting with the EMEA sets the stage for the Phase IIb efficacy trial of inecalcitol for prostate cancer. |
|
|
Meet us at the AACR-NCI-EORTC International Conference 'Molecular Targets and Cancer Therapeutics' (November 15-19, 2009; Boston, USA) . A poster will be presented by Dr. Frédéric Colland in Poster Session B on Tuesday, 17th November (12:30 p.m.-2:30 p.m. and 5:30 p.m.-7:30 p.m). |
|
|
Paris, 8 october 20009 - Hybrigenics announces preclinical results demonstrating the potential of inecalcitol alone and in a synergistic combination with a cytotoxic platinum derivative, to inhibit the growth of a human hormone-dependent prostate cancer cell line. These results are presented today at the 14th Vitamin D Workshop in Brugge by Dr Ryoko Okamoto. |
|
|
Meet us at the 'Ubiquitin Drug Discovery and Diagnostics 2009' international conference (October 12-14, 2009; Philadelphia, USA ). An oral presentation will be given by Dr. Frédéric Colland during the session 'Emerging Targets in Oncology' scheduled at 4:45 p.m. on Tuesday, 13th October. |
|
Paris, 22 September 2009 - update on the interim results from its phase II clinical trial of inecalcitol in patients with hormone-refractory prostate cancer. The update is the subject of a poster presentation at the 34th annual meeting of the European Society for Medical Oncology in Berlin, Germany.......(read more) |
|
Article in Molecular Cancer Therapeutics shows the anticancer potential of an inhibitor of ubiquitin-specific protease n°7 (Colland et al., Mol Cancer Ther (2009) 8, 2286-95)
Paris, 24 August 2009 - publication of a scientific article in Molecular Cancer Therapeutics showing the anticancer potential of HBX41,108, its lead small molecule inhibitor of ubiquitin-specific protease n°7 (USP7)......(read more) |
|
Paris, June 16th, 2009 - The results of the ongoing clinical tolerance Phase II study in hormone-refractory
prostate cancer patients demonstrate that daily oral doses as high as 1,000 microgram (microgram), i.e. 1 milligram (mg) of inecalcitol per day, are very well tolerated. |
|
|
Meet us at the 4th International meeting of the intracellular proteolysis network on 'Ubiquitin-Proteasome System Dynamics and Targeting' (May 27-29, 2009; Barcelona, Spain) . An oral presentation will be given by Dr. Frédéric Colland during the session 'drug discovery in the ubiquitin-proteasome system' scheduled at 11:40 a.m. on Friday, 29th May and a poster will be presented the same day in poster session 3 (3:00 p.m. - 5:30 p.m.). |
|
|
Paris, April, 17th 2009 - Hybrigenics will present interim results at the 2009 Meeting of the American Society of Clinical Oncology (ASCO) in Orlando, Florida on May 31 |
|
Successful pre-IND meeting with the FDA sets the stage for the development of inecalcitol for prostate cancer in the United States.Paris, March 12, 2009 - Hybrigenics announced today the comprehensive review by the American Food and Drug Administration of the pharmaceutical, preclinical and clinical information on inecalcitol. A proposal for a two-step efficacy development plan for hormone-refractory prostate cancer in combination with Taxotere® has been accepted. |
|
|
Paris, December 11, 2008 – Hybrigenics announced today it has been granted the first in a series of patent applications covering the company’s proprietary chemical inhibitors of Ubiquitin-Specific Proteases (USPs). Company expects significant patent activity in near and medium term |
|
|
Meet us at the International Conference 'International Drug Discovery Science & Technology, IDDST 2008' (October 18-22, 2008; Pekin, China) . An oral presentation will be given during the session 'Oncology & drug discovery' scheduled for 1:30 p.m. - 5:30 p.m. on Saturday, 18th October. |
|
|
|
|
Paris, June 17, 2008 - Hybrigenics announced today that France’s regulatory agency AFSSAPS has authorized the company to increase inecalcitol dosage in Hybrigenics’ Phase II clinical trial currently underway for patients suffering from hormone-refractory prostate cancer. |
|
|
Paris, June 4, 2008 - Hybrigenics today announces the renewal of a scientific contract with Servier Laboratories. The contract covers the validation of a confidential ubiquitin-specific protease (USP) involved in the regulation of a protein of special interest for Servier Laboratories in the field of oncology. |
|
|
Meet us at the International Conference 'Drug targets in the Ubiquitin Proteasome System; Targeting the ubiquitin system for drug discovery and development ' (March 10-12, 2008; Berlin, Germany). An oral presentation will be given during the session 'E3 Ligase and DUB inhibitors' scheduled for 2:00 p.m. - 5:00 p.m. on Wednesday, 12th March. |
|
|
Meet us at the AACR International Conference 'Ubiquitin and Cancer: From Molecular Targets and Mechanisms to the Clinic' (January 22-25, 2008; San Diego, CA). Our abstract has been selected for an oral presentation that will be given during the session 'Ubiquitin, transcription and epigenetics' scheduled for 4:00 p.m. - 5:00 p.m. on Thursday, January 24. |
|
|
Meet us at the AACR-NCI-EORTC International Conference ‘Molecular Targets and Cancer Therapeutics’ (October 22-27, 2007 * San Francisco, CA) during the Poster session ‘Other Small Molecule Therapeutic Agents’ (Abstract # C220) on Thursday, October 25 from 12:30 to 7:30PM. |
|
Hybrigenics’ inecalcitol shows high level of tolerance
Paris, April 12, 2007- Hybrigenics successfully performs first clinical trial -Hybrigenics announces today the first results from its Phase I clinical trial of inecalcitol, a synthetic analogue of vitamin D under development by Hybrigenics as a potential treatment for prostate cancer.
|
|
Hybrigenics focuses its research on inhibitors of ubiquitin-specific proteases in cancer Dutch subsidiary sells non-core research patents
Paris, February 20, 2007 - Hybrigenics announces today that it is concentrating its research efforts on ubiquitin-specific proteases (USPs) and their inhibitors in cancer. Consequently, Hybrigenics has divested the patent portfolio of Semaia, its Dutch subsidiary, on the Wnt-pathway and the EPAC targets. |
|
Hybrigenics acquires worldwide rights to inecalcitol, a vitamin D analogue
Paris, February 7, 2006. - Hybrigenics SA announced that it has acquired a license for the worldwide exclusive rights to inecalcitol, a synthetic analogue of vitamin D, for all clinical indications. Hybrigenics intends to focus on an oral formulation to develop inecalcitol in cancer indications, such as advanced androgen-independent prostate cancer, and expects this acquisition to rapidly move its R&D pipeline towards clinical development. |
|
NiKem Research Srl and Hybrigenics SA Significantly Expand their Research Service Agreement in the Oncology Area
Milan and Paris— May 10th, 2005 - NiKem Research Srl and Hybrigenics SA announced today that they have expanded and extended a Research Service Agreement already in place between the two companies. Under the terms of the agreement, NiKem will continue using its medicinal chemistry platform and expertise to optimize inhibitors of Ubiquitin Specific Proteases (USP) as new therapeutic agents against cancer. This family of proteases has been the focus of thorough target identification and validation studies by Hybrigenics in the field of Oncology. |
|
